Sheath use not linked with strictures

Publication
Article
Urology Times JournalVol 48 No 3
Volume 48
Issue 03

A study of kidney stone patients who were treated using ureteral access sheaths found no evidence of ureteral strictures an average of 4 years following ureteroscopy.

Chicago-A study of kidney stone patients who were treated using ureteral access sheaths found no evidence of ureteral strictures an average of 4 years following ureteroscopy.

The results are intriguing, given that some urologists believe there are too little data to ascertain whether the use of ureteral access sheaths puts patients at risk of ureteral injury (World J Urol 2015; 33:2137-44). Also notable: The results held true regardless of the diameter of the sheath used, the size of the stone, length of operating time, or gender.

However, given the small sample size-157 patients-“This is an area where more study is needed,” Jose Eduardo Castro Matheus Rodrigues, a research student at the Massachusetts General Hospital department of urology, Boston and a medical student at University of São Paulo-Brazil, told AUA 2019 attendees.

Read: Sequential gemcitabine/docetaxel promising for recurrent NMIBC

The study was conducted under Brian Eisner, MD, of the Massachusetts General Hospital department of urology and Harvard Medical School, Boston.

Results from the study are based on a retrospective review of patients who have undergone ureteroscopy procedures that involved use of a ureteral access sheath. Patients included in the study also had a follow-up visit 1 year or more after the procedure and received an abdominal imaging scan.

While recent studies have shown that placement of ureteral access sheaths during ureteroscopy can cause ureteral lesions, such as when too much force is applied (J Endourol 2019; 33:712-8), the long-term consequences of deploying ureteral access sheaths are not yet known. This study sought to determine the impact of using ureteral access sheaths on the patient’s chances of developing a ureteral stricture in the first year or more after surgery.

Next: Average follow-up time of 4 yearsAverage follow-up time of 4 years

Among the 157 patients who met these criteria, 56% were men and 44% were women, the average age of patients was 61 years (range, 27 to 96 years), and the average follow-up time was 4.1 years (range, 1 to 8 years).

The authors recorded the diameter of the ureteral access sheath used, with 95% of patients being treated with a sheath that had a diameter of 11/13 Fr or larger. The mean diameter of the largest stone removed during ureteroscopy was 6.9 mm (range, 2 to 26 mm), and the average operating time was 31 minutes (range, 10.5 to 108 minutes). Leakage of contrast material was noted in 5% of patients (eight patients).

The authors also noted the types of follow-up imaging used to examine whether use of a ureteral access sheath had caused a ureteral stricture to form. These included renal ultrasound (104 patients), computerized tomography (45 patients), and magnetic resonance imaging (seven patients).

Also see: Panel issues urology-specific opioid Rx recommendations

The results showed that during the patients’ most recent follow-up visit, none of the patients demonstrated persistent hydronephrosis, and no patients had undergone treatment for a ureteral stricture or displayed radiographic evidence of a stricture.

Previous studies on this topic have lacked long-term follow-up data, Rodrigues said. The availability of medium-term follow-up data is critical to advancing discussion around this controversial approach.

Related Videos
Kevin M. Wymer, MD
Video 7 - "Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer"
Video 6 - "Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape"
Video 5 - "Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer"
Video 4 - "Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis"
Video 3 - "Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life"
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"
Related Content
© 2024 MJH Life Sciences

All rights reserved.